Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services.

Dao, Kim; Shechtman, Svetlana; Weber-Schoendorfer, Corinna; Diav-Citrin, Orna; Murad, Reem Hegla; Berlin, Maya; Hazan, Ariela; Richardson, Jonathan L; Eleftheriou, Georgios; Rousson, Valentin; Diezi, Leonore; Haefliger, David; Simões-Wüst, Ana Paula; Addor, Marie-Claude; Baud, David; Lamine, Faiza; Panchaud, Alice; Buclin, Thierry; Girardin, François R and Winterfeld, Ursula (2024). Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ open, 14(4), e083550. BMJ Publishing Group 10.1136/bmjopen-2023-083550

Preview

Text e083550.full.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (970kB) | Preview

OBJECTIVES

Glucagon-like peptide 1 receptor agonists (GLP1-RA) are indicated for the treatment of type 2 diabetes and more recently for weight loss. The aim of this study was to assess the risks associated with GLP1-RA exposure during early pregnancy.

DESIGN

This multicentre, observational prospective cohort study compared pregnancy outcomes in women exposed to GLP1-RA in early pregnancy either for diabetes or obesity treatment with those in two reference groups: (1) women with diabetes exposed to at least one non-GLP1-RA antidiabetic drug during the first trimester and (2) a reference group of overweight/obese women without diabetes, between 2009 and 2022.

SETTING

Data were collected from the databases of six Teratology Information Services.

PARTICIPANTS

This study included 168 pregnancies of women exposed to GLP1-RA during the first trimester, alongside a reference group of 156 pregnancies of women with diabetes and 163 pregnancies of overweight/obese women.

RESULTS

Exposure to GLP1-RA in the first trimester was not associated with a risk of major birth defects when compared with diabetes (2.6% vs 2.3%; adjusted OR, 0.98 (95% CI, 0.16 to 5.82)) or to overweight/obese (2.6% vs 3.9%; adjusted OR 0.54 (0.11 to 2.75)). For the GLP1-RA group, cumulative incidence for live births, pregnancy losses and pregnancy terminations was 59%, 23% and 18%, respectively. In the diabetes reference group, corresponding estimates were 69%, 26% and 6%, while in the overweight/obese reference group, they were 63%, 29% and 8%, respectively. Cox proportional cause-specific hazard models indicated no increased risk of pregnancy losses in the GLP1-RA versus the diabetes and the overweight/obese reference groups, in both crude and adjusted analyses.

CONCLUSIONS

This study offers reassurance in cases of inadvertent exposure to GLP1-RA during the first trimester of pregnancy. Due to the limited sample size, larger studies are required to validate these findings.

Interest & Impact

Downloads

10 since deposited on 01 May 2024
10 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item